Bridgebio Pharma Stock Operating Margin
| BBIO Stock | USD 27.77 1.28 4.83% |
BridgeBio Pharma fundamentals help investors to digest information that contributes to BridgeBio Pharma's financial success or failures. It also enables traders to predict the movement of BridgeBio Stock. The fundamental analysis module provides a way to measure BridgeBio Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BridgeBio Pharma stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (65.29) | (62.02) |
BridgeBio | Operating Margin |
BridgeBio Pharma Company Operating Margin Analysis
BridgeBio Pharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BridgeBio Pharma Operating Margin | (68.50) % |
Most of BridgeBio Pharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BridgeBio Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BridgeBio Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for BridgeBio Pharma is extremely important. It helps to project a fair market value of BridgeBio Stock properly, considering its historical fundamentals such as Operating Margin. Since BridgeBio Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BridgeBio Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BridgeBio Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
BridgeBio Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, BridgeBio Pharma has an Operating Margin of -68.4952%. This is 95.25% higher than that of the Biotechnology sector and 38.88% lower than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
BridgeBio Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BridgeBio Pharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BridgeBio Pharma could also be used in its relative valuation, which is a method of valuing BridgeBio Pharma by comparing valuation metrics of similar companies.BridgeBio Pharma is currently under evaluation in operating margin category among its peers.
BridgeBio Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of BridgeBio Pharma from analyzing BridgeBio Pharma's financial statements. These drivers represent accounts that assess BridgeBio Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BridgeBio Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.7B | 8.4B | 2.4B | 1.1B | 6.6B | 6.9B | |
| Enterprise Value | 3.4B | 8.5B | 3.7B | 2.5B | 7.9B | 8.3B |
BridgeBio Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BridgeBio Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Pharma's managers, analysts, and investors.Environmental | Governance | Social |
BridgeBio Fundamentals
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (68.50) % | ||||
| Current Valuation | 6.71 B | ||||
| Shares Outstanding | 188.99 M | ||||
| Shares Owned By Insiders | 5.42 % | ||||
| Shares Owned By Institutions | 94.13 % | ||||
| Number Of Shares Shorted | 17 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 24.76 X | ||||
| Revenue | 9.3 M | ||||
| Gross Profit | 74.21 M | ||||
| EBITDA | (565.47 M) | ||||
| Net Income | (643.2 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 1.74 B | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (6.51) X | ||||
| Cash Flow From Operations | (527.72 M) | ||||
| Short Ratio | 6.82 X | ||||
| Earnings Per Share | (2.42) X | ||||
| Price To Earnings To Growth | 0.05 X | ||||
| Target Price | 48.89 | ||||
| Number Of Employees | 550 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 5.39 B | ||||
| Total Asset | 546.38 M | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 333.75 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
| Net Asset | 546.38 M |
About BridgeBio Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BridgeBio Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BridgeBio Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BridgeBio Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with BridgeBio Stock
Moving against BridgeBio Stock
| 0.6 | VIGL | Vigil Neuroscience | PairCorr |
| 0.52 | VALN | Valneva SE ADR | PairCorr |
| 0.5 | DTIL | Precision BioSciences | PairCorr |
| 0.49 | DRRX | Durect | PairCorr |
| 0.33 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BridgeBio Pharma Piotroski F Score and BridgeBio Pharma Altman Z Score analysis. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.